1 week Ago By Defense World Staff
Ultragenyx Pharmaceutical Inc. ( NASDAQ:RARE – Free Report ) – Stock analysts at Wedbush upped their FY2027 earnings per share estimates for Ultragenyx Pharmaceutical in a report issued on Thursday, January 23rd. Wedbush analyst L.
Chico now expects that the biopharmaceutical company will earn $1.05 per share for the year, up from their previous estimate of $1.04.
Wedbush has a “Neutral” rating and a $48.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($6.
14) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical’s FY2028 earnings at $1.92 EPS.
Ultragenyx Pharmaceutical ( NASDAQ:RARE – Get Free Report ) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, topping analysts’ consensus estimates of ($1.
45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.
12% and a negative net margin of 106.93%. The firm had revenue of $139.
49 million during the quarter, compared to analyst estimates of $135.28 million. During the same period last year, the company earned ($2.
23) earnings per share. The business’s revenue for the quarter was up 42.3% on a year-over-year basis.
View Our Latest Stock Analysis on Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical Stock Performance Shares of RARE stock opened at $44.05 on Friday. Ultragenyx Pharmaceutical has a 52-week low of $37.
02 and a 52-week high of $60.37. The company has a market capitalization of $4.
07 billion, a PE ratio of -6.81 and a beta of 0.58.
The business’s fifty day moving average is $44.56 and its 200 day moving average is $49.62.
Insider Buying and Selling at Ultragenyx Pharmaceutical In other news, CEO Emil D. Kakkis sold 8,273 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $50.
00, for a total transaction of $413,650.00. Following the completion of the sale, the chief executive officer now owns 2,195,712 shares of the company’s stock, valued at $109,785,600.
The trade was a 0.38 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link .
Company insiders own 5.80% of the company’s stock. Institutional Investors Weigh In On Ultragenyx Pharmaceutical A number of hedge funds have recently modified their holdings of RARE.
True Wealth Design LLC bought a new position in Ultragenyx Pharmaceutical in the 3rd quarter worth $43,000. Values First Advisors Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $56,000.
Wilmington Savings Fund Society FSB purchased a new stake in Ultragenyx Pharmaceutical during the 3rd quarter valued at $83,000. Nomura Asset Management Co. Ltd.
purchased a new stake in Ultragenyx Pharmaceutical during the 3rd quarter valued at $93,000. Finally, R Squared Ltd bought a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at $103,000. Institutional investors own 97.
67% of the company’s stock. About Ultragenyx Pharmaceutical ( Get Free Report ) Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
See Also Five stocks we like better than Ultragenyx Pharmaceutical The 3 Best Retail Stocks to Shop for in August Bloom Energy: Powering the Future With Decentralized Energy Learn Technical Analysis Skills to Master the Stock Market Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul The Most Important Warren Buffett Stock for Investors: His Own Why Traders Are Buying the Dip on Johnson & Johnson Stock Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter ..
